Evidence of ≥2 prescription claims for enzalutamide or darolutamide during the identification period with the first occurrence of ARPI treatment defined as the index date
Male patients with a diagnosis of mHSPC or nmCRPC before or on the index date
Aged ≥55 years on the index date
You may not be if
Use of any of the ARPIs (abiraterone, apalutamide, enzalutamide, and darolutamide), Evidence of CRPC prior to the index date for mHSPC
Evidence of metastasis before index date + 30 days for nmCRPC
Clareo Health | A Study to Learn About Heart-Related Risks in Elderly Men With Advanced Prostate Cancer Treated With Enzalutamide or Darolutamide
